HillaryHWuMD

Oncology • Carmel, IN

Physician at Indiana University Health

Join to view full profile

Dr. Wu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wu's full profile

Already have an account?

Office
11645 Illinois St
Carmel, IN 46032
Phone+1 317-688-5964

Education & Training

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 2000 - 2003
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1997 - 2000
Beijing Medical UniversityClass of 1987

Certifications & Licensure

IN State Medical License 2000 - 2025
CO State Medical License 2002 - 2023
NC State Medical License 2002 - 2019
AL State Medical License 2002 - 2018
WA State Medical License 2002 - 2013
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Indianapolis Monthly Castle Connolly, 2011, 2013
Top MD Consumers Checkbook

Clinical Trials

A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors Start of enrollment: 2011 Mar 01
Completed
Phase 1
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Start of enrollment: 2010 Jan 01
Completed
Phase 1, Phase 2
Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma Start of enrollment: 2010 Jul 01
Terminated
Phase 1, Phase 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma Start of enrollment: 2012 Jan 01
Completed
Phase 2
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2013 Jan 18
Active, not recruiting
Phase 2
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. Start of enrollment: 2013 May 14
Completed
Phase 4
Join now to see all

Publications & Presentations

PubMed

11 citations
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluor...
Tracy Murray Stewart, Daniel D. Von Hoff, Michael L. Fitzgerald, Laurence J. Marton, Carlos Becerra
Cancer Chemotherapy and Pharmacology. 2021-01-01
10 citations
Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer
Donald A. Richards, David M. Loesch, Svetislava J. Vukelja, Hillary H. Wu, William J. Hyman
Investigational New Drugs. 2011-10-01
17 citations
Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
Hillary H. Wu, Moshe Talpaz, Richard E. Champlin, R R N Susan Pilat, Razelle Kurzrock
Cancer. 2003-12-01